Jefferies Lifts Target on Abbott Labs (ABT) After Carving Out AbbVie
Get Alerts ABT Hot Sheet
Price: $116.64 +2.19%
Rating Summary:
26 Buy, 9 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Rating Summary:
26 Buy, 9 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Join SI Premium – FREE
Jefferies boosted its price target on Buy-rated Abbott Labs (NYSE: ABT) from $75 to $85 after carving out split-off AbbVie in their model.
"We now value AbbVie at $55 per share with the remaining Abbott business (DMP) valued at $30 per share, making our new PT $85," the analyst said.
"Abbott remains our top pick through 2012 and we see a strong set of newsflow and valuation drivers over the next 6 months."
FY12 EPS was raised from $5.71 to $5.83 and FY13 from $6.30 to $6.36.
For an analyst ratings summary and ratings history on Abbott Labs click here. For more ratings news on Abbott Labs click here.
Shares of Abbott Labs closed at $68.91 yesterday.
"We now value AbbVie at $55 per share with the remaining Abbott business (DMP) valued at $30 per share, making our new PT $85," the analyst said.
"Abbott remains our top pick through 2012 and we see a strong set of newsflow and valuation drivers over the next 6 months."
FY12 EPS was raised from $5.71 to $5.83 and FY13 from $6.30 to $6.36.
For an analyst ratings summary and ratings history on Abbott Labs click here. For more ratings news on Abbott Labs click here.
Shares of Abbott Labs closed at $68.91 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abbott Labs (ABT) PT Raised to $135 at TD Cowen
- Walmart (WMT) PT Lowered to $125 at JPMorgan, Overweight Rating Maintained as 'Short Case Feels Greedy'
- Emkay Global Starts Urban Company (URBANCO:IN) at Buy (1)
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT ChangeRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share